ECho: Efficacy of Inhaled GSK2339345 in Chronic Idiopathic Cough
Research type
Research Study
Full title
A randomised, double-blind (sponsor-unblind), placebo controlled, cross-over study to investigate the efficacy, effect on cough reflex sensitivity, safety, tolerability and pharmacokinetics of inhaled GSK2339345 in patients with chronic idiopathic cough using an aqueous droplet inhaler
IRAS ID
130280
Contact name
Jaclyn Smith
Contact email
Eudract number
2012-004891-20
ISRCTN Number
N/A
Research summary
Chronic cough is a protective reflex action which is used to clear the upper airways, and yet it is the most common complaint for which medical advice is sought. Most coughs are caused by an upper respiratory tract infection, which is fought by the immune system and settles within 8 weeks (defined as acute cough). However, some people develop persistent coughing which can last from 8 weeks to several years. This persistent cough is known as ‘chronic cough’. There are currently no effective treatments available for people with chronic cough.
This research aims to look at whether a research drug called GSK2339345 can help to reduce the amount a person coughs compared to placebo and also test its safety and tolerability. The drug will be inhaled using a new inhaler device.
We aim to recruit up to 30 people with chronic cough to take part in this study. Taking part will involve nine visits to the University Hospital of South Manchester to undertake a variety of tests including cough monitoring, cough challenge tests, heart tracings, blood pressure monitoring, breathing tests, questionnaires and blood tests.
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
13/YH/0232
Date of REC Opinion
6 Sep 2013
REC opinion
Further Information Favourable Opinion